Catalent Secures Exclusive AAV Manufacturing Rights in Ultra-Rare Disease Deal
Event summary
- Catalent partners with Elpida Therapeutics for late-phase AAV9 gene therapy manufacturing for Spastic Paraplegia Type 50 (SPG50).
- Catalent gains exclusive manufacturing rights to Elpida’s other AAV gene therapy programs.
- Catalent will use its UpTempoTM AAV manufacturing platform to accelerate production for regulatory submission.
- SPG50 is an ultra-rare neurodegenerative disorder with no current treatment options.
The big picture
This deal underscores Catalent’s push into late-phase gene therapy manufacturing, particularly for ultra-rare diseases where traditional biotech firms often deprioritize development. The partnership highlights the growing role of CDMOs in bridging gaps in orphan drug development, where patient populations are small but unmet medical needs are critical. Catalent’s exclusive rights to Elpida’s pipeline programs could position it as a key player in the gene therapy manufacturing space.
What we're watching
- Regulatory Progress
- The pace at which Elpida advances toward Biologics License Application submission with Catalent’s support.
- Manufacturing Scale
- Whether Catalent can sustain production capacity for multiple ultra-rare disease programs.
- Pipeline Expansion
- How Catalent leverages exclusive rights to Elpida’s other AAV programs for future partnerships.
Related topics